This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
Leukemia Open Access 29 April 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Campbell PJ, Green AR . The myeloproliferative disorders. New Engl J Med 2006; 355: 2452–2466.
Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108: 346–352.
Sidon P, El Housni H, Dessars B, Heimann P . The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006; 20: 1622.
McClure R, Mai M, Lasho T . Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006; 20: 168–171.
Passamonti F, Rumi E, Pietra D, Lazzarino M, Cazzola M . JAK2 (V617F) mutation in healthy individuals. Br J Haematol 2007; 136: 678–679.
Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB et al. JAK2(V617F): prevalence in a large Chinese hospital population. Blood 2007; 109: 339–342.
Biernaux C, Loos M, Sels A, Huez G, Stryckmans P . Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118–3122.
Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV . The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362–3367.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Bellanné-Chantelot, C., Jego, P., Lionne-Huyghe, P. et al. The JAK2V617F mutation may be present several years before the occurrence of overt myeloproliferative disorders. Leukemia 22, 450–451 (2008). https://doi.org/10.1038/sj.leu.2404896
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404896
This article is cited by
-
Novel germline mutation KMT2A G3131S confers genetic susceptibility to familial myeloproliferative neoplasms
Annals of Hematology (2021)
-
Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies
Nature Genetics (2015)
-
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
Leukemia (2010)
-
Low burden of a JAK2-V617F mutated clone in monoclonal haematopoiesis in a Japanese woman with Budd-Chiari syndrome
International Journal of Hematology (2009)
-
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders
Leukemia (2008)